BM-MNCs and UC-MSCs Infusion for Type 2 Diabetes Mellitus Patients (T2DM)

This is an interventional treatment trial for Type 2 Diabetes Mellitus Read More

Inclusion Criteria:

• Who is diagnosed with Type 2 Diabetes Mellitus according to the ADA 3 years or more
• Patients are able to read, write and understand ICF form and agree to participate in the study
• Males and females between age 18 and 70 years at the screening.
• FBG > 7 mmol/L
• 8% ≤ HbA1C ≤ 11%
• Fasting C-peptide > 0.6 ng/ml
• Anti GAD (-)
• The patient is treated by two oral diabetes medications but uncontrolled blood glucose (HbA1C ≥ 8%)

Exclusion Criteria:

• Pregnant women, planning to become pregnant and lactating women during the study period
• The patient has a disease or a history of vascular disease; history of abdominal or chest aortic disease;
• Patients are diagnosed with heart failure degree IV according to NYHA or kidney failure degree IV according to KDIGO;
• Patients with severe malignancy or dysplasia within 5 years prior to the study period or who are suffering from severe malignant or dysplasia
• Infection is undergoing antibiotic treatment or antibiotics have just been discontinued within 14 days
• Hematologic disease or coagulopathy
• There are abnormalities in liver function (AST and/or ALT ≥ 2 times or bilirubin ≥ 2.0 times normal value at the time of screening);
• Patients with immunodeficiency diseases such as HIV or hepatitis B and C;
• Acute or chronic pancreatitis or a history of acute pancreatitis;
• Patients taking immunosuppressive drugs (such as azathioprine, methotrexate) within 6 months before the study time or taking immunosuppressive drugs;
• The patient is unable to complete the study;
• The patient is participating in another study.